IA
KERX

IFP Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

IFP Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,000
Closed -$43K – 4294
2017
Q3 		$43K Sell
6,000
-5,335
-47% -$38.4K ﹤0.01% 2085
2017
Q2 		$82K Buy
11,335
+5,335
+89% +$33.3K ﹤0.01% 1650
2017
Q1 		$37K Hold
6,000
– – ﹤0.01% 2119
2016
Q4 		$35K Hold
6,000
– – ﹤0.01% 2092
2016
Q3 		$32K Hold
6,000
– – ﹤0.01% 2114
2016
Q2 		$40K Buy
+6,000
New +$33.5K ﹤0.01% 1919
2016
Q1 		– Sell
-6,000
Closed -$30K – 3890
2015
Q4 		$30K Buy
+6,000
New +$28.5K ﹤0.01% 1932

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IFP Advisors's KERX Position: Q4 2017 in Review

IFP Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 6,000 shares — an estimated $43K sold.

IFP Advisors first reported a position in KERX in Q4 2015 and held it in 7 quarters. The position peaked at $82K in Q2 2017. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • IFP Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • IFP Advisors sold 6,000 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $43K.
  • IFP Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 7 quarters.
  • IFP Advisors's Keryx Biopharmaceuticals Inc position peaked at $82K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on IFP Advisors's 13F filing for Q4 2017, filed 24 Jan 2018.